Use of Midodrine in Septic Shock Patients
Phase 2
Recruiting
- Conditions
- Low Blood PressureSepsis
- Interventions
- Other: Standard of Care
- Registration Number
- NCT06319248
- Lead Sponsor
- Mayo Clinic
- Brief Summary
This study is being done to determine if early administration of Midodrine can improve outcomes by maintaining a higher mean blood pressure off of intravenous medications. Researchers want to see if Midodrine can help people with sepsis need fewer vasopressors, which could mean shorter hospital stays, less time with uncomfortable tubes, and a smoother recovery overall.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 270
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Standard of Care Group Standard of Care - Standard of Care with Midodrine Group Midodrine -
- Primary Outcome Measures
Name Time Method Time alive and without vasopressor support 28 days Measured in hours
- Secondary Outcome Measures
Name Time Method Total vasopressor requirements 28 days Measured as norepinephrine equivalents (µg)
Central venous access duration 28 days Measured in hours
Cumulative fluid balance up to 7 days of ICU stay 7 days ICU Length of Stay 28 days Total number of days admitted to the Intensive Care Unit (ICU)
Hospital Length of Stay 28 days Total number of days admitted to the hospital
ICU, hospital, and organ support-free days 28 days Number of ICU, hospital, and organ support-free days
Cumulative fluid balance over the first 48 hours 48 hours
Trial Locations
- Locations (1)
Mayo Clinic Minnesota
🇺🇸Rochester, Minnesota, United States